Apellis Pharmaceuticals Stock Insider Trading

Healthcare > Biotechnology

Buy APLS

*Your capital is at risk

$41.03

+0 (+0%)

At Close: Jul 23, 2026

Apellis Pharmaceuticals Stock Insider Power

Based on the 100 latest insides trades, we have calculated the insider power to be negative at -74.47. In total, the insiders bought 488.56K and sold 4.62M APLS shares in the last 100 trades. The insider score can be negative despite buy/sell ratio being positive. The score focuses on the quality of the trades.

Insider Power (Last 100 transactions)	-74.47
● Buy	488.56K shares
● Sell	4.62M shares
18% Buy Activity Negligible or No Correlation
Sell Signal High Confidence May 14, 2026 Analysis Breakdown: Strongly supported by a very low Insider Power Score of -74.47. Confidence increased due to high data reliability score of 100. Supported by overwhelming sell-side pressure (18% buys).

Historical Insider Trades

Date	Type	Person	Role	Amount
May 14, 2026 Buy	Common Stock A-Award	Sullivan Timothy Eugene Chief Financial Officer	C-Suite Officer	58 140 Value: $2.39M
May 14, 2026 Sell	Stock Option (right to buy) D-Return	Sullivan Timothy Eugene Chief Financial Officer	C-Suite Officer	84 946 Value: $1.18M
May 14, 2026 Sell	Stock Option (right to buy) D-Return	Sullivan Timothy Eugene Chief Financial Officer	C-Suite Officer	232 903 Value: $2.34M
May 14, 2026 Sell	Stock Option (right to buy) D-Return	Sullivan Timothy Eugene Chief Financial Officer	C-Suite Officer	45 000 Value: $2.02M
May 14, 2026 Sell	Stock Option (right to buy) D-Return	Sullivan Timothy Eugene Chief Financial Officer	C-Suite Officer	70 125 Value: $3.11M
May 14, 2026 Sell	Common Stock U-Tender	Sullivan Timothy Eugene Chief Financial Officer	C-Suite Officer	71 492 Value: $286.0K
May 14, 2026 Sell	Stock Option (right to buy) D-Return	Sullivan Timothy Eugene Chief Financial Officer	C-Suite Officer	60 242 Value: $2.14M
May 14, 2026 Sell	Stock Option (right to buy) D-Return	Sullivan Timothy Eugene Chief Financial Officer	C-Suite Officer	82 500 Value: $1.60M
May 14, 2026 Sell	Stock Option (right to buy) D-Return	Sullivan Timothy Eugene Chief Financial Officer	C-Suite Officer	23 958 Value: $358.2K
May 14, 2026 Buy	Common Stock A-Award	Sullivan Timothy Eugene Chief Financial Officer	C-Suite Officer	29 070 Value: $1.19M
May 14, 2026 Buy	Common Stock A-Award	Sullivan Timothy Eugene Chief Financial Officer	C-Suite Officer	30 620 Value: $1.26M
May 14, 2026 Sell	Common Stock D-Return	Machiels Alec Director	Director	3 544 Value: $0
May 14, 2026 Sell	Stock Option (right to buy) D-Return	Machiels Alec Director	Director	8 554 Value: $404.4K
May 14, 2026 Sell	Stock Option (right to buy) D-Return	Deschatelets Pascal Chief Scientific Officer	Officer	95 000 Value: $1.32M
May 14, 2026 Buy	Common Stock A-Award	Deschatelets Pascal Chief Scientific Officer	Officer	10 030 Value: $411.5K
May 14, 2026 Buy	Common Stock A-Award	Deschatelets Pascal Chief Scientific Officer	Officer	25 840 Value: $1.06M
May 14, 2026 Buy	Common Stock A-Award	Deschatelets Pascal Chief Scientific Officer	Officer	41 250 Value: $1.69M
May 14, 2026 Sell	Stock Option (right to buy) D-Return	Machiels Alec Director	Director	27 600 Value: $1.58M
May 14, 2026 Sell	Stock Option (right to buy) D-Return	Deschatelets Pascal Chief Scientific Officer	Officer	82 500 Value: $1.60M
May 14, 2026 Sell	Common Stock D-Return	Deschatelets Pascal Chief Scientific Officer	Officer	25 840 Value: $0
May 14, 2026 Sell	Common Stock U-Tender	Deschatelets Pascal Chief Scientific Officer	Officer	1 177 222 Value: $118
May 14, 2026 Sell	Common Stock U-Tender	Chan Gerald Director	Director	25 666 Value: $3
May 14, 2026 Sell	Stock Option (right to buy) D-Return	Chan Gerald Director	Director	8 554 Value: $404.4K
May 14, 2026 Sell	Stock Option (right to buy) D-Return	Chan Gerald Director	Director	11 199 Value: $357.4K
May 14, 2026 Sell	Stock Option (right to buy) D-Return	Dunlop A. Sinclair Director	Director	8 554 Value: $404.4K

About Insider Power

Insider Power is a proprietary algorithm developed by StockInvest.us to evaluate the significance of insider transactions. The calculation considers the size, type, and timing of transactions, as well as the insider’s role within the company.

It is important to note that, in general, there is little to no correlation between insider transactions and short-term stock price movements. In one of our studies, only 0.22%^* of stocks with insider activity showed a measurable correlation — and even then, it was unclear whether the effect was caused by insider actions or simply by the stock’s broader trend.

While our algorithms are designed to highlight potentially meaningful signals, these cannot be regarded as statistically significant on their own. Insider trading activity should therefore be seen as informative rather than as direct trading guidance. The Insider Power metric was created to present this information in a clearer and more accessible way, helping investors better understand the possible context of insider activity.

* October 6th, 2025 - Tested on 5562 stocks

ABOUT APELLIS PHARMACEUTICALS INC.

Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy (GA) in age-related macular degeneration and paroxysmal nocturnal ...

Read Full Profile Here